BEIJING – Multinational antibody specialist Hifibio Therapeutics Inc. said it closed a $67 million series C financing round to advance its drug candidates for cancer and autoimmune disorders.
BEIJING – Chinese startup Biotheus Inc., of Zhuhai, Guangdong, has its sights fixed on bispecific and multitarget antibodies to maximize drug efficacy. A biotech innovator based in the south of China, it gained support from local authorities that aim to create another biotech hub in the country.
BEIJING – Multinational antibody specialist Hifibio Therapeutics Inc. said it closed a $67 million series C financing round to advance its drug candidates for cancer and autoimmune disorders.
BEIJING – The trade war has escalated. On Aug. 23, China announced retaliatory tariffs on $75 billion of U.S. exports, 10 days after the U.S. slapped the same amount on $300 billion of Chinese goods. Once again, the med-tech sector is neck deep in this tariff tit-for-tat.
BEIJING – Innovent Biologics Inc., of Suzhou, China, has in-licensed diabetes drug OXM-3 from Eli Lilly and Co. to develop and commercialize it in China.
BEIJING – With home-grown artificial intelligence (AI) medical devices under priority review, mainland China is quickly putting together a regulatory framework to more rapidly tap into the power of AI to develop devices and drugs.
BEIJING – Innovent Biologics Inc., of Suzhou, China, has in-licensed diabetes drug OXM-3 from Eli Lilly and Co. to develop and commercialize it in China.
BEIJING – Fibrogen Inc. said its first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (previously FG-4592) won a second approval in China to include more patients with anemia caused by chronic kidney disease (CKD). China, again, is the first market to grant the company the nod to treat patients who are not dialysis-dependent.
BEIJING – Fibrogen Inc. said its first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (previously FG-4592) won a second approval in China to include more patients with anemia caused by chronic kidney disease (CKD). China, again, is the first market to grant the company the nod to treat patients who are not dialysis-dependent.
BEIJING – With home-grown artificial intelligence (AI) medical devices under priority review, mainland China is quickly putting together a regulatory framework to more rapidly tap into the power of AI to develop devices and drugs.
